Stay Ahead of Compliance with Monthly Citation Updates


In your State Survey window and need a snapshot of your risks?

Survey Preparedness Report

One Time Fee
$79
  • Last 12 months of citation data in one tailored report
  • Pinpoint the tags driving penalties in facilities like yours
  • Jump to regulations and pathways used by surveyors
  • Access to your report within 2 hours of purchase
  • Easily share it with your team - no registration needed
Get Your Report Now →

Monthly citation updates straight to your inbox for ongoing preparation?

Monthly Citation Reports

$18.90 per month
  • Latest citation updates delivered monthly to your email
  • Citations organized by compliance areas
  • Shared automatically with your team, by area
  • Customizable for your state(s) of interest
  • Direct links to CMS documentation relevant parts
Learn more →

Save Hours of Work with AI-Powered Plan of Correction Writer


One-Time Fee

$49 per Plan of Correction
Volume discounts available – save up to 20%
  • Quickly search for approved POC from other facilities
  • Instant access
  • Intuitive interface
  • No recurring fees
  • Save hours of work
F0756
D

Failure to Act on Pharmacist Medication Regimen Review Recommendations

Honolulu, Hawaii Survey Completed on 05-15-2025

Penalty

No penalty information released
tooltip icon
The penalty, as released by CMS, applies to the entire inspection this citation is part of, covering all citations and f-tags issued, not just this specific f-tag. For the complete original report, please refer to the 'Details' section.

Summary

The facility failed to ensure that recommendations made by the consultant licensed pharmacist (CLP) during the monthly medication regimen review (MRR) were acted upon for a resident. Specifically, for a male resident with diagnoses including spinal stenosis, atrial fibrillation, and anxiety disorder, one MRR recommendation regarding a gradual dose reduction (GDR) or clinical contraindication (CC) for Trazadone was not followed up in a timely manner. Although a provider eventually declined the recommendation, documentation of timely review and follow-up was lacking. Additionally, another MRR recommendation noted the discontinuation of Trazadone and the initiation of Lexapro, with a plan to discuss the change at the next psychotropic meeting. However, there was no documentation available to confirm that this discussion took place, as the requested psychotropic meeting minutes were not provided. The DON confirmed that unit managers are responsible for reviewing MRRs within one week, but the absence of documentation indicates this process was not consistently followed.

An unhandled error has occurred. Reload 🗙